EUVIMEDEUVIMED entdecken
Fallbericht

Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report

Alice S Zhao, Yi Liu, Joseph J Mulvey, Beverly G Tchang

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07243-w ↗

Kurz gefasst

Fallbericht in der Zeitschrift Osteoporosis International, 2024. Verfasst von Alice S Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: New York Presbyterian Weill Cornell Medical College, New York, NY, USA. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Osteoporosis, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a metabolic bone disorder for which treatment options include antiresorptive therapies (e.g., bisphosphonates, denosumab); anabolics (e.g., teriparatide, abaloparatide); and dual mechanisms (e.g., romosozumab). Management of osteoporosis with concurrent antiresorptive and anabolic agents may be superior to monotherapy, as demonstrated in the DATA trial with the combination of denosumab and teriparatide. However, there is limited experience with the combination of denosumab and romosozumab, which may be an alternative antiresorptive/anabolic regimen for individuals who are not candidates for PTH receptor agonists. In this case, we present a young man with glucocorticoid-induced osteoporosis who could not tolerate a daily injectable anabolic and who experienced improvement in bone mineral density with concurrent denosumab and off-label romosozumab administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone Density Conservation AgentsOsteoporosisGlucocorticoidsBone DensityAntibodies, MonoclonalDrug Therapy, CombinationHumansMaleAdult

Stichwörter der Autor:innen

DenosumabOsteoporosisRomosozumab

Substanzen

DenosumabBone Density Conservation AgentsromosozumabGlucocorticoidsAntibodies, Monoclonal

Autor:innen und Institutionen

  • New York Presbyterian Weill Cornell Medical College, New York, NY, USA.
  • Weill Cornell Medicine, New York, NY, USA.
  • Montefiore Medical Center, New York, NY, USA.
  • Weill Cornell Medicine, New York, NY, USA. bgt9001@med.cornell.edu.

Zitieren

APA

Zhao, A. S., Liu, Y., Mulvey, J. J., & Tchang, B. G. (2024). Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report. Osteoporosis International. https://doi.org/10.1007/s00198-024-07243-w

Vancouver

Zhao AS, Liu Y, Mulvey JJ, Tchang BG. Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report. Osteoporosis International. 2024. doi:10.1007/s00198-024-07243-w

BibTeX
@article{Zhao2024,
  author = {Zhao, Alice S and Liu, Yi and Mulvey, Joseph J and Tchang, Beverly G},
  title = {Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07243-w}
}
Kostenlos starten →